ClinicalTrials.gg

Program

D-methadone

Also written as “REL-1017” and “REL1017 (esmethadone HCI) (active drug)”.

Its studies are mostly in Depressive Disorder, Major · Neuralgia, led by 3 companies.

Furthest: phase 3, since Dec 7, 20209 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Relmada Therapeutics60 open or runningphase 3since Dec 7, 2020Feb 3, 2017none ahead
Levomecor20 open or runningphase 3since Apr 19, 2021Apr 19, 2021none ahead
MGGM10 open or runningphase 3since Dec 13, 2024Dec 13, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 3, 2017First study: phase 2 study in Depressive Disorder, MajorNew to Relmada TherapeuticsRelmada Therapeutics · NCT03051256 · 62 enrolled · United States
  2. Aug 10, 20182 phase 1 studies in NeuralgiaRelmada Therapeutics · NCT03638869, NCT03637361
  3. Dec 7, 2020Phase 3 study in Depressive Disorder, MajorRelmada Therapeutics · NCT04688164 · 227 enrolled · United States
  4. Apr 19, 2021Phase 3 study in Depressive Disorder, MajorRelmada Therapeutics · NCT04855760 · 627 enrolled · United States
  5. Apr 19, 2021Levomecor's first study: phase 3 study in Depressive Disorder, MajorNew to LevomecorLevomecor · NCT04855747 · 236 enrolled · United States
  6. Oct 4, 2021Phase 3 study in Depressive Disorder, MajorRelmada Therapeutics · NCT05081167 · 232 enrolled · United States
  7. Aug 21, 2023Phase 3 study in Depressive Disorder, MajorLevomecor · NCT06011577 · 27 enrolled · United States
  8. Dec 13, 2024MGGM's first study: phase 3 study in Depressive Disorder, MajorNew to MGGMMGGM · NCT06735079 · Italy, Switzerland

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06735079Depressive Disorder, Major · Italy, Switzerland3WithdrawnMGGMDec 1, 20260
NCT06011577Depressive Disorder, Major · United States3TerminatedLevomecorDec 19, 202427
NCT05081167Depressive Disorder, Major · United States3CompletedRelmada TherapeuticsSep 13, 2022232
NCT04855760Depressive Disorder, Major · United States3CompletedRelmada TherapeuticsJul 27, 2023627
NCT04855747Depressive Disorder, Major · United States3TerminatedLevomecorDec 31, 2024236
NCT04688164Depressive Disorder, Major · United States3CompletedRelmada TherapeuticsNov 1, 2022227
NCT03638869Neuralgia1CompletedRelmada TherapeuticsNov 16, 201524
NCT03637361Neuralgia1CompletedRelmada TherapeuticsJun 2, 201542
NCT03051256Depressive Disorder, Major · United States2CompletedRelmada TherapeuticsJul 30, 201962

How it is read

Names in the registry

  • “REL-1017”, 8 entries
  • “REL1017 (esmethadone HCI) (active drug)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.